Rubitor 2 mg/ml (IV Infusion)

10 mg vial: ৳ 950.00

Medicine Details

Therapeutic Class

  • Cytotoxic Chemotherapy

Indications

  • Component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer

Pharmacology

  • Anthracycline with cytotoxic properties
  • Inhibits DNA and RNA synthesis
  • Generates cytotoxic free radicals
  • Distribution into tissues
  • Metabolized by the liver
  • Eliminated through biliary and urinary excretion
  • Terminal elimination half-life is 30-40 hrs

Dosage & Administration

  • Administered by intravenous infusion
  • Given in repeated 3-to 4-week cycles
  • Total dose may be given on day 1 or divided and given on days 1 and 8 of each cycle
  • Recommended dose is 100 to 120 mg/m²
  • Specific regimens recommended
  • Prophylactic antibiotic therapy recommended for certain regimen

Interaction

  • Close monitoring with concomitant use of cardioactive compounds
  • Cimetidine increases exposure
  • Additive toxicity with other cytotoxic drugs
  • Increased systemic exposure with Paclitaxel and Docetaxel
  • Inflammatory recall reaction with previous radiation therapy
  • Metabolism affected by concomitant therapies

Contraindications

  • Known hypersensitivity to Epirubicin or other anthracyclines or anthracenediones or any other components

Side Effects

  • Myelosuppression
  • Cardiotoxicity
  • Alopecia
  • Nausea
  • Vomiting
  • Diarrhea
  • Fever
  • Rash
  • Anorexia
  • Harmless reddish appearance of urine for 1-2 days

Pregnancy & Lactation

  • Pregnancy Category D
  • No adequate and well-controlled studies in pregnant women
  • Potential risk to the fetus
  • Potential serious adverse reactions in nursing infants

Precautions & Warnings

  • Gelling when stored at refrigerated conditions
  • Careful visual inspection prior to administration
  • Administration under supervision of qualified physicians
  • Recovery from acute toxicities of prior cytotoxic treatment before beginning Rubitor
  • Baseline assessment of blood counts, serum levels, and cardiac function
  • Monitoring for myelosuppression and cardiotoxicity

Use in Special Populations

  • Dosage adjustments based on toxicities within a cycle of treatment
  • Considerations for bone marrow dysfunction, hepatic impairment, renal impairment, pediatric use, and geriatric use

Overdose Effects

  • Supportive treatment if overdose occurs
  • Observation for delayed CHF

Storage Conditions

  • Store in refrigerator or at 2-8°C
  • Do not freeze
  • Protect from light
  • Keep out of the reach of children

Related Brands